Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 2221 to 2235 of 8202 results

  1. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA [TSID11883]

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

    Awaiting development [GID-TA11607] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510]

    Awaiting development [GID-TA11635] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development [GID-TA10993] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]

    Awaiting development [GID-TA11596] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]

    Awaiting development [GID-TA11490] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Aprocitentan for treating resistant hypertension [TSID10395]

    Awaiting development [GID-TA11459] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    Awaiting development [GID-TA11440] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Lenacapavir for treating multidrug resistant HIV-1 [ID6196]

    Suggested remit: To appraise the clinical and cost effectiveness of lenacapavir within its marketing authorisation for treating multidrug resistant HIV-1 for wh...

    Technology appraisal guidance
    Topic selection

  14. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

      Status ...

    Health technology evaluations
    Topic selection

  15. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

      Status ...

    Technology appraisal guidance
    Topic selection